Alan Hruza
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Cancer-related Molecular Pathways, Computational Drug Discovery Methods, Microtubule and mitosis dynamics
Most-Cited Works
- → Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors(2013)676 cited
- → Structural characterization of nitric oxide synthase isoforms reveals striking active-site conservation.(1999)454 cited
- → Structure of the insulin receptor–insulin complex by single-particle cryo-EM analysis(2018)262 cited
- → Zinc mediated dimer of human interferon-α2b revealed by X-ray crystallography(1996)224 cited
- → Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases(2010)175 cited
- → Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity(2017)143 cited
- → Discovery of Selective RNA-Binding Small Molecules by Affinity-Selection Mass Spectrometry(2018)107 cited
- → Structure‐guided discovery of cyclin‐dependent kinase inhibitors(2007)67 cited
- → Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2(2007)65 cited
- → Dissecting Therapeutic Resistance to ERK Inhibition(2016)52 cited